Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Aquestive Therapeutics, Inc. Common Stock

AQST

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Last trade $3.69
Day change -$0.075 (-1.99%)
Day range $3.67 – $3.81
Volume 1,553,343
Market cap $473M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$472.59M
Price / earnings
—
Price / book
-6.67×
Price / sales
9.68×
EV / sales
8.87×
EV / EBITDA
-7.65×

Profitability

Earnings per share
-$0.63
Return on assets
-66.44%
Return on equity
111.94%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.72×
Current ratio
6.12×
Quick ratio
5.69×
Cash ratio
5.22×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AQST, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$7.56M$13.82M$14.45M$13.02M$12.81M$10M$8.72M$11.87M
Cost of revenue$3.61M$4.02M$3.47M$5.84M$4.51M$4.56M$3.65M$4.52M
Gross profit$3.95M$9.8M$10.98M$7.18M$8.3M$5.44M$5.07M$7.35M
Selling, general and administrative$14.17M$14.06M$10.98M$32.82M$15.25M$12.71M$19.07M$16.01M
Research and development$4.25M$3.96M$4.2M$3.2M$4.53M$4.11M$5.36M$4.92M
Total operating expenses$18.42M$18.03M$15.18M$37.45M$19.78M$16.81M$24.43M$22.31M
Operating income-$14.47M-$8.22M-$4.2M-$30.27M-$11.48M-$11.37M-$19.37M-$14.96M
Interest expense-$2.88M-$3.84M-$3.94M-$2.84M-$4.27M-$4.28M-$4.28M-$2.84M
Income before taxes-$16.5M-$22.86M-$8.06M-$31.86M-$15.45M-$13.55M-$22.93M-$17.07M
Income taxes$0$0$0$0$0$0$0-$14K
Net income-$16.5M-$22.86M-$8.06M-$31.86M-$15.45M-$13.55M-$22.93M-$17.06M
Net income attributable to common shareholders-$16.5M-$22.86M-$8.06M-$31.86M-$15.45M-$13.55M-$22.93M-$17.06M
EBITDA-$14.31M-$8.09M-$4.09M-$30.14M-$11.34M-$11.23M-$19.23M-$14.82M
Basic earnings per share-$0.13-$0.18-$0.07-$0.26-$0.14-$0.14-$0.24-$0.19
Diluted earnings per share-$0.13-$0.18-$0.07-$0.26-$0.14-$0.14-$0.24-$0.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. The company is also advancing its Canadian regulatory submission planned for Q4 2026.

GlobeNewswire Inc.

AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.

GlobeNewswire Inc.

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.

GlobeNewswire Inc.

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role

A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquestive's stock price plummeted 37% from $6.21 to $3.91 per share. Investors who purchased shares between June 16, 2025 and January 8, 2026 have until May 4, 2026 to apply as lead plaintiff.

GlobeNewswire Inc.

Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.